XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.93

+2.9%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (13986)	7/5/2000 11:06:50 AM
From: aknahow	Read Replies (3) of 17367

Blugreen, Oak Tree is a physician. He probably understands medicine, but he does not understand Robert. Oak Tree posted, (" I hold with Robert, specifically, the natural BPI in the blood didn't work"). This is not what Robert believes. Robert feels P III did not work because the placebo group did get BPI in the transfusions. The fact that all subjects, in both arms of the trial, got at least two units of blood, also apparently was not clear to Oak Tree. Like talking to a tree, people ignore your clear statement of the problem. ""Once again how can you have a trial such as Hemo Trauma when your endpoint disappears by 50%????"" But for this, I blame XOMA. They have never again repeated this information confirming that this indeed was the case. In fact, they have said that the data was not unblinded and needed to be analyzed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next